5 New Drug Approvals Pharmacy Techs Should Know

MAY 11, 2016
Ryan Marotta, Assistant Editor
Learn about the new drugs and expanded indications approved by the FDA in April 2016.
1. Bevespi Aerosphere
The FDA approved AstraZeneca’s glycopyrrolate and formoterol fumarate (Bevespi Aerosphere) inhalation aerosol on April 25, 2016. The twice-daily, fixed-dose dual bronchodilator is indicated for the long-term maintenance treatment of chronic obstructive pulmonary disease (COPD).
Notably, Bevespi Aerosphere is the first FDA-approved combination of a long-acting muscarcinic antagonist (LAMA) and a long-acting beta-2 agonist (LABA) to be administered via a pressurized metered-dose inhaler.
“LAMA/LABAs are emerging as a preferred treatment option for many COPD patients,” said AstraZeneca executive vice president Sean Bohen in a press release. “This class aims to provide maximum bronchodilation, which enables patients to breathe better and may help them be more active.”
The most common adverse event reported by trial participants treated with Bevespi Aerosphere were urinary tract infection and cough.